Improved haemoglobin concentrations with IV darbepoetin alfa - Case studies of haemodialysis patients

Current Medical Research and Opinion

Volumn 18, Issue 7, 2002, Pages 440-444

  Thiele, A ^a,b   Wittner, M ^a  

^a Klinikum Rosenheim   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anaemia; Chronic renal failure; Darbepoetin alfa; Erythropoietin; Haemoglobin

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

AGED; ANEMIA; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 0036453657     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125001182     Document Type: Article

References (24)

1. Levin A. Anaemia in the patient with renal insufficiency: Documenting the impact and reviewing treatment strategies. Nephrol Dial Transpl 1999;14:292-5
2. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999;10:1793-800
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(Suppl 3):S112-9
4. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-54
5. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-92
6. Comorbid conditions and correlations with mortality risk among 3399 incident hemodialysis patients. Am J Kidney Dis 1992;20(Suppl 2):S32-8
7. Romagnoli GF, Naso A, Carraro G, Lidestri V. Beneficial effects of L-carnitine in dialysis patients with impaired left ventricular function: An observational study. Curr Med Res Opin 2002;18(3):172-5
8. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transpl 1999;14(Suppl 5):1-50
9. Jacobs C, Hörl WH, Macdougall IC et al. European best practice guidelines 5: Target haemoglobin. Nephrol Dial Transpl 2000;15:15-9
10. Jacobs C, Hörl WH, Macdougall IC et al. European best practice guidelines 9-13: Anaemia management. Nephrol Dial Transpl 2000;15:33-42
11. Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-5
12. Aranesp® Summary of Product Characteristics. Thousand Oaks: Amgen Inc.; 2001. http://www.amgen.com
13. Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000;20:375-81
14. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transpl 2001;16(Suppl 3):14-21
15. Locatelli F, Olivares J, Walker R et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741-7
16. Vanrenterghem Y, Bárány P, Kerr P et al. Novel Erythropoiesis Stimulating Protein (NESP) for Maintaining Haemoglobin at a Reduced Dose Frequency Compared with Erythropoietin in Dialysis Patients. Submitted for publication 2002
17. Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial Transpl 2002;17(Suppl 1):48-52
18. Bárány P. Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transpl 2001;16:224-7
19. Whittington P, Barradell LB, Benfield P. Epoetin: A pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life. Pharmacoeconomics 1993;3:45-82
20. Murphy ST, Parfrey PS. The impact of anemia correction on cardiovascular disease in end-stage renal disease. Semin Nephrol 2000;20:350-5
21. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000;20:345-9
22. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transpl 2001;16:307-12
23. Macdougall IC, Ritz E. The normal haematocrit trial in dialysis patients with cardiac disease: Are we any less confused about target haemoglobin? Nephrol Dial Transpl 1998;13:3030-3
24. Macdougall IC. Higher target haemoglobin level and early anaemia treatment: Different or complimentary concepts? Nephrol Dial Transpl 2000;15:3-7